Drug Details
| General Information of the Drug (ID: DR9830) | ||||
|---|---|---|---|---|
| Name |
HSV-TK/GCV
|
|||
| Disease | Fallopian tube cancer [ICD-11: 2C74] | Phase 2 | [1] | |
| Ovarian cancer [ICD-11: 2C73] | Phase 2 | [2] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | Cx32 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | GJA1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | B16 | CVCL_F936 | Mouse melanoma | Mus musculus | ||
| In-vivo Model | A total of 2*105 B16 cells in a final volume of 100L was injected into the right flanks of each C57BL/6J mouse. | |||||
| Experimental
Result(s) |
Curcumin could enhance the killing effect and the bystander effect of HSV-TK/GCV in treating melanoma, which might be mediated by improved gap junction. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Bacterial Listeriolysin regulatory (Bact prfA) | Molecule Info | [4] | |
| Mycobacterium Lumazine synthase (MycB ribH) | Molecule Info | [4] | ||
| Thymidine kinase 1 (TK1) | Molecule Info | [4] | ||
